Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, small-molecule inhibitor targeting the catalytic domains of ROCK1 and ROCK2 with nanomolar affinity, exhibiting >200-fold selectivity over unrelated kinases (APExBIO). It disrupts Rho-mediated stress fiber formation and modulates cell cycle progression, making it essential in studies of stem cell viability, cytoskeletal organization, and tumor invasion (Zhu et al., 2023). The compound demonstrates high solubility in DMSO, ethanol, and water and is stable when stored below -20°C as a solid. In vitro and in vivo studies validate its role in reducing cell proliferation and tumor metastasis (internal). APExBIO supplies Y-27632 dihydrochloride (SKU A3008) for robust, reproducible Rho/ROCK pathway interrogation.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) regulate actin cytoskeleton dynamics, cell motility, and contractility. Activation of the Rho/ROCK pathway induces formation of actin stress fibers and focal adhesions, affecting processes such as cytokinesis, cell migration, and proliferation (Zhu et al., 2023). Dysregulation of ROCK activity is linked to tumor invasion, metastasis, and stem cell viability. Selective pharmacological inhibition of ROCK kinases enables precise modulation of these pathways for mechanistic and translational research. Y-27632 dihydrochloride is widely adopted as a reference ROCK inhibitor for dissecting Rho-mediated cellular functions and disease mechanisms (see comparison).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride acts as a competitive ATP-binding site inhibitor of ROCK1 and ROCK2. It binds the catalytic domains, blocking substrate phosphorylation and downstream signaling. The compound exhibits an IC₅₀ of ~140 nM for ROCK1 and a K_i of 300 nM for ROCK2, with >200-fold selectivity against kinases such as PKC, PKA, MLCK, and PAK (APExBIO). Inhibition of ROCK prevents RhoA-mediated actin stress fiber formation, disrupts cell contractility, and impairs G1-S cell cycle progression and cytokinesis. This targeted mechanism enables researchers to specifically interrogate the Rho/ROCK signaling axis without broad off-target effects (clarification).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM in biochemical assays (APExBIO).
• Displays >200-fold selectivity for ROCK1/2 over unrelated kinases (PKC, PKA, MLCK, PAK) in kinase profiling panels (APExBIO).
• Suppresses Rho-mediated actin stress fiber formation and focal adhesion assembly in fibroblasts and smooth muscle cells (Zhu et al., 2023).
• Reduces prostatic smooth muscle cell proliferation in vitro in a dose-dependent manner (e.g., 10 μM, 24–72 h) (internal).
• Diminishes tumor invasion and metastasis in mouse models via oral or intraperitoneal administration (doses: 10–30 mg/kg) (internal).
• Enhances viability and survival of human pluripotent stem cells post-dissociation (Zhu et al., 2023).
• Stock solutions are stable for several months at -20°C; solid form should be stored desiccated at 4°C or lower (APExBIO).

This article extends the practical integration advice provided in 'Y-27632 Dihydrochloride: Precision ROCK Inhibitor for Cytoskeletal Studies' by detailing quantitative selectivity data and solubility parameters for experimental reproducibility.

For advanced 3D cancer modeling, see 'Y-27632 Dihydrochloride: Precision ROCK Inhibition in 3D Systems', which this article updates with in vivo tumor invasion benchmarks.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely used in:

• Stem Cell Research: Enhances survival of human pluripotent stem cells after single-cell dissociation (Zhu et al., 2023).
• Cytoskeleton Studies: Disrupts Rho/ROCK-dependent actin stress fiber formation for mechanistic studies.
• Cancer Biology: Inhibits tumor cell invasion and metastasis in preclinical models (internal).
• Cell Cycle and Proliferation Assays: Blocks G1-S progression and cytokinesis in dose- and time-dependent manner.
• Assay Development: Used as a benchmark control for Rho/ROCK pathway interrogation.

Common Pitfalls or Misconceptions

• Y-27632 dihydrochloride does not inhibit upstream RhoA activation; it targets only ROCK1/2 catalytic domains.
• The compound is not suitable for long-term (>1 week) continuous culture due to potential off-target effects at high concentrations (>10 μM).
• Not effective as an anti-seizure drug in vivo; its main use is in cell and animal models for mechanistic studies (Zhu et al., 2023).
• Does not block all actin cytoskeletal remodeling, as alternative pathways (e.g., LIMK, cofilin) remain active.
• Solubility issues may arise at high concentrations in aqueous buffers; DMSO or ethanol is recommended for stock solutions.

Workflow Integration & Parameters

Y-27632 dihydrochloride (A3008, APExBIO) is supplied as a solid and should be stored desiccated at 4°C or below. Stock solutions (≥111.2 mg/mL in DMSO; ≥17.57 mg/mL in ethanol; ≥52.9 mg/mL in water) are best prepared by warming to 37°C or using an ultrasonic bath for dissolution. Aliquots stored below -20°C are stable for several months. For cell-based assays, working concentrations typically range from 1 to 10 μM, with exposure durations from 30 minutes to 72 hours depending on endpoint (APExBIO). Avoid repeated freeze-thaw cycles and prolonged storage of solutions. For detailed troubleshooting and protocol optimization, see 'Y-27632 Dihydrochloride (SKU A3008): Reliable ROCK Inhibitor for Cell Assays', which this article extends by providing updated selectivity and in vivo efficacy data.

Conclusion & Outlook

Y-27632 dihydrochloride is a gold-standard, cell-permeable, and highly selective ROCK1/2 inhibitor for research on cytoskeletal dynamics, stem cell viability, and tumor metastasis. Its validated potency, selectivity, and solubility profile enable reproducible Rho/ROCK pathway interrogation across diverse assays. As new mechanistic and translational insights into ROCK signaling emerge, Y-27632 dihydrochloride (A3008, APExBIO) will remain an essential reagent for both basic and applied biomedical research. For ordering and full specifications, refer to the Y-27632 dihydrochloride product page.